Intrexon Corporation is a biotechnology organization focused on the development of advanced genetic therapeutics designed to address complex and severe diseases. Leveraging synthetic biology, multi-function gene programs, and proprietary cellular engineering technologies, Intrexon aims to produce targeted therapies for aggressive cancers, neurological disorders, and cardiac failure. Known for its research rigor and innovation ecosystem, the company collaborates with research institutions, pharmaceutical organizations, and clinical partners to accelerate therapeutic discovery. Over decades, Intrexon has established itself as a leader in gene-based drug development, building a diversified biomedical portfolio supported by strong scientific and investor backing.
What Is Intrexon Corporation and What Does It Do?
Intrexon Corporation, founded in 1998 in Germantown, United States, by Thomas Reed, is a biotechnology company developing gene-based therapies for complex human diseases. It focuses on engineering multi-function gene programs and cell systems to treat advanced cancers, cardiac disorders, and neurodegenerative conditions. Intrexon employs between 501–1,000 people, spanning research, laboratory science, regulatory work, and clinical development.
The company operates across synthetic biology, immunology, and therapeutic gene engineering. Its platform integrates controlled gene expression technologies, cellular pathways, and targeted delivery systems to create next-generation, high-precision therapeutics capable of addressing unmet medical needs.
How Much Funding Has Intrexon Corporation Raised?
1. Post IPO
- Amount Raised: $4.25M
- Date: March 2016
- Motivation: To support late-stage R&D and strengthen therapeutic development initiatives.
2. Post IPO
- Amount Raised: $4.25M
- Date: February 2016
- Motivation: To further expand research infrastructure and clinical programs.
3. Post IPO
- Amount Raised: $450K
- Date: February 2015
- Motivation: To bolster ongoing innovation in gene-therapy research.
Total Funding Raised: $709M
Latest Funding Date: March 2016
Key Investors
1. Third Security
- Details: A venture capital firm focused on biotech and life sciences.
- Investment Focus Areas: Synthetic biology, healthcare, precision medicine.
- Notable Investments: Intrexon, Harvest Intrexon, Fibrocell, GenVec, Ziopharm.
2. Fidelity Investments
- Details: Global financial services firm supporting late-stage innovation.
- Investment Focus Areas: Healthcare, therapeutics, biotech.
- Notable Investments: Moderna, Amgen, Vertex, Illumina, Ginkgo Bioworks.
Where Is Intrexon’s Headquarters?
Intrexon is headquartered in Germantown, Maryland, offering proximity to major research institutions, regulatory agencies, and biotechnology talent clusters.
What’s Next for Intrexon?
Future initiatives for Intrexon involve accelerating clinical development, enhancing synthetic biology platforms, and expanding therapies reaching trial readiness. The company continues to invest in gene activation compounds, targeted delivery systems, and broader therapeutic pipelines.
Get Investor & Funding Insights with TexAu
TexAu helps sales and business teams uncover detailed fundraising information on companies like Intrexon. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign Up for Free on TexAu and start uncovering detailed funding insights that give your business a competitive edge.
